Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 155 of 6351
-
Immunotherapy combo shows promise against stomach cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil \[FP regimen\] or oxaliplatin combined with capecitabine \[CAPOX regimen\]) versus placebo in combination with chemotherapy (F…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control OngoingIn this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a heal…
Phase 1/2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail shows promise for myeloma patients ineligible for transplant
Disease control CompletedThe purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Womb surgery breakthrough: two methods to fix spina bifida before birth
Disease control OngoingThe purpose of this study is to evaluate the feasibility and effectiveness of performing fetoscopic surgical correction of fetal spina bifida. Two surgical approaches will be utilized: the percutaneous technique versus the laparotomy/uterine exteriorization technique.
Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail shows promise in slowing advanced prostate cancer
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytot…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Heart attack prevention shot tested in 16,000 patients
Disease control OngoingORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol: CTSU\_MDCO-PCS-17-01 (CKJX839B12301)). The study aims to find out if a new cholesterol-lowering injection (inclisiran) safely lowers the risk o…
Phase 3 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill shows promise against lung cancer brain metastases
Disease control CompletedThe first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell lung c…
Phase 2/3 • Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC
-
Leukemia drug cocktail aims to boost remission in High-Risk patients
Disease control CompletedThis study will test the effectiveness and safety of Venetoclax in combination with standard induction regimen for patients with acute leukemia and poor prognosis.
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immunotherapy combo shows promise for advanced cervical cancer
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women wit…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can lower chemo doses help babies with SCID build better immunity?
Disease control OngoingThe investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to su…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Immunotherapy combo shows promise in advanced nasopharyngeal cancer trial
Disease control CompletedThis is a randomized, placebo-controlled, multi-center, double blinded, Phase III study to determine the efficacy and safety of TORIPALIMAB INJECTIO(JS001) in combination with gemcitabine/cisplatin compared with placebo in combination with gemcitabine/cisplatin as first-line trea…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 13:19 UTC
-
New drug cocktail shows promise in battle against advanced ovarian cancer
Disease control OngoingOvarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian …
Phase 3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Trikafta shows promise for long-term cystic fibrosis control
Disease control CompletedThe study evaluates the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Immunotherapy boosts standard care for HER2-Positive stomach cancer?
Disease control CompletedThe study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug may beat standard therapy in aggressive leukemia
Disease control OngoingIn this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs o…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can focused ultrasound replace watchful waiting for prostate cancer?
Disease control OngoingThe percentage of malignant prostate tumors detected very early is constantly increasing and the number of well differentiated tumors, with small volume and low risk of progression increases. When a tumor of this type is identified, radical prostatectomy remains the reference tre…
Phase 3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Womb fluid injections could give babies with no kidneys a chance to breathe
Disease control Recruiting nowCongenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to t…
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Immunotherapy combo aims to stop lung cancer return after chemoradiation
Disease control OngoingThis is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a new pill boost Immunotherapy's power against advanced tumors?
Disease control CompletedThis clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary anti-tumor activity of FLX475 as monotherapy and in combination with pembrolizumab. The study will be conducted in 2 parts, a dose…
Phase 1/2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Experimental shot before surgery may keep melanoma from coming back
Disease control Recruiting nowThe trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery …
Phase 3 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC